AbbVie Inc. Quarterly Deferred Income Tax Liabilities, Net in USD from Q4 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Summary
AbbVie Inc. quarterly Deferred Income Tax Liabilities, Net history and growth rate from Q4 2019 to Q3 2024.
  • AbbVie Inc. Deferred Income Tax Liabilities, Net for the quarter ending September 30, 2024 was $2.75B, a 34.5% increase year-over-year.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Deferred Income Tax Liabilities, Net, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $2.75B +$705M +34.5% Sep 30, 2024 10-Q 2024-11-04
Q2 2024 $2.73B +$602M +28.3% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $2.72B +$612M +29% Mar 31, 2024 10-Q 2024-05-03
Q4 2023 $1.95B -$238M -10.9% Dec 31, 2023 10-Q 2024-11-04
Q3 2023 $2.04B +$72M +3.65% Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $2.12B -$131M -5.81% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $2.11B -$721M -25.5% Mar 31, 2023 10-Q 2023-05-05
Q4 2022 $2.19B -$819M -27.2% Dec 31, 2022 10-K 2024-02-20
Q3 2022 $1.97B -$1.63B -45.3% Sep 30, 2022 10-Q 2022-11-04
Q2 2022 $2.26B -$1.41B -38.4% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $2.83B -$937M -24.9% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $3.01B -$637M -17.5% Dec 31, 2021 10-K 2023-02-17
Q3 2021 $3.6B -$883M -19.7% Sep 30, 2021 10-Q 2021-11-02
Q2 2021 $3.66B -$1.12B -23.5% Jun 30, 2021 10-Q 2021-08-02
Q1 2021 $3.77B +$2.81B +293% Mar 31, 2021 10-Q 2021-05-07
Q4 2020 $3.65B +$2.52B +223% Dec 31, 2020 10-K 2022-02-18
Q3 2020 $4.49B Sep 30, 2020 10-Q 2020-11-04
Q2 2020 $4.79B Jun 30, 2020 10-Q 2020-08-04
Q1 2020 $959M Mar 31, 2020 10-Q 2020-05-08
Q4 2019 $1.13B Dec 31, 2019 10-K 2021-02-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.